clinical trial · NCT05795361
Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome
Takeda·—·available
Hunter SyndromeIdursulfase-IT
brief summary
As the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies are completed and closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.
started
—
primary completion
—
completion
—
last updated
Apr 13, 2026
official title
Post-trial Access Program: Idursulfase-IT (HGT-2310) in Conjunction With Intravenous Elaprase® in Pediatric and Adult Patients With Hunter Syndrome and Cognitive Impairment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol